[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:epithelioid-hemangioendothelioma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":35,"states":36},"Epithelioid Hemangioendothelioma",4,[7,15,22,29],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07104331","SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma",[11],"Phase 2","RECRUITING","2026-08-26T02:16:21.385056Z","2026-05-05T02:43:26.686204Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06452160","A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors",[19],"Phase 1","2026-08-26T02:17:29.353236Z","2026-05-05T02:43:27.312630Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT06725758","A Phase 1\u002F2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours",[26],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.568386Z",[],[37],{"state":38,"count":39,"slug":40},"Missouri",3,"missouri"]